The study, which focused on U.S. veterans who were hospitalized for COVID-19, concluded that remdesivir was not associated with improved survival, but was associated with longer hospital stays. The drug was granted emergency use authorization by the FDA for the treatment of hospitalized COVID-19 patients in May 2020, and the Infectious Diseases Society of America and NIH currently recommend it for patients hospitalized with severe COVID-19. About 20.7% of those who had received remdesivir were admitted to the ICU versus 19.1% in the control group, and 5.9% needed ventilator support versus 3.8% who did not. The patients who received remdesivir averaged about six days in the hospital versus three days for those who had not. "In this cohort study of U.S. veterans hospitalized with COVID-19, remdesivir treatment was not associated with improved survival but was associated with longer hospital stays," the researchers concluded.

Source: Fox News July 15, 2021 16:52 UTC